Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rubius Therapeutics, Inc.    RUBY

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
9.04(c) 9.18(c) 8.85(c) 9.69(c) 9.48(c) Last
339 228 250 789 290 722 712 028 603 340 Volume
-5.14% +1.55% -3.59% +9.49% -2.17% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -170 M - -
Net cash position 2020 150 M - -
P/E ratio 2020 -4,50x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -187 M - -
Net cash position 2021 193 M - -
P/E ratio 2021 -4,69x
Yield 2021 -
Capitalization 767 M 767 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 197
Free-Float 90,8%
More Financials
Company
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes,... 
More about the company
Notations Surperformance© of Rubius Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about RUBIUS THERAPEUTICS, INC.
01/12RUBIUS THERAPEUTICS : Provides Operational Update and Outlines 2021 Objectives a..
AQ
01/11RUBIUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
01/11RUBIUS THERAPEUTICS : Provides Operational Update and Outlines 2021 Objectives a..
AQ
01/05RUBIUS THERAPEUTICS : to Present at the Virtual 39th Annual J.P. Morgan Healthca..
AQ
01/04Rubius Therapeutics to Present at the Virtual 39th Annual J.P. MorganáHealthc..
GL
2020Rubius Therapeutics to Participate in Evercore ISIá3rd AnnualáHealthCONx Conf..
GL
2020RUBIUS THERAPEUTICS : Named to the List of Top Places to Work in Massachusetts b..
AQ
2020Morgan Stanley Adjusts Rubius Therapeutics PT to $5 From $4, Maintains Equal ..
MT
2020RUBIUS THERAPEUTICS : to Participate in Jefferies Virtual London Healthcare Conf..
AQ
2020Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Con..
GL
2020Rubius Therapeutics Q3 Loss Narrower YOY But Wider Than Expected
MT
2020RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
2020RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
2020RUBIUS THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Strong Ex..
AQ
2020Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong E..
GL
More news
News in other languages on RUBIUS THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on RUBIUS THERAPEUTICS, INC.
More recommendations
Chart RUBIUS THERAPEUTICS, INC.
Duration : Period :
Rubius Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RUBIUS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 9,57 $
Last Close Price 9,48 $
Spread / Highest target 195%
Spread / Average Target 0,96%
Spread / Lowest Target -68,4%
EPS Revisions
Managers and Directors
NameTitle
Pablo J. Cagnoni Chief Executive Officer & Director
David R. Epstein Executive Chairman
Joanne M. Protano Senior Vice President-Finance & Operations
Jose Carmona Treasurer, Chief Financial & Accounting Officer
Spencer Fisk Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
RUBIUS THERAPEUTICS, INC.24.90%767
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458